Antimicrobial Resistance in Klebsiella pneumoniae: Mechanisms, Epidemiology, and Emerging Threats
References
- Ambler R.P, Coulson A.F, Frere J.M, Ghuysen J.M, Joris B, Forsman M, Levesque R.C, Tiraby G, Waley S.G. A standard numbering scheme for the class A β–lactamases. Biochemical Journal. 1991;276:269–270.
http://doi.org/10.1042/bj2760269 - Arakawa Y. Systematic research to overcome newly emerged multidrug–resistant bacteria. Microbiology and Immunology. 2020;64:231–251.
http://doi.org/10.1111/1348-0421.12781 - Asokan S, Jacob T, Jacob J, AlSosowaa A.A, Cherian T, Peijnenburg W.J.G.M, Vijayan S. Klebsiella pneumoniae: A growing threat in the era of antimicrobial resistance. The Microbe. 2025;7:100333.
http://doi.org/10.1016/j.microb.2025.100333 - Bader M.S, Loeb M, Leto D, Brooks A.A. Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents. Postgraduate Medicine. 2020;32:234–250.
http://doi.org/10.1080/00325481.2019.1680052 - Bahr G, González L.J, Vila A.J. Metallo-β-lactamases and a tug–of–war for the available zinc at the host-pathogen interface. Current Opinion in Chemical Biology. 2021;66:102103.
http://doi.org/10.1016/j.cbpa.2021.102103 - Baraniak A, Fiett J, Mrówka A, Walory J, Hryniewicz W, Gniadkowski M. Evolution of TEM-Type Extended–Spectrum β-Lactamases in Clinical Enterobacteriaceae Strains in Poland. Antimicrobial Agents and Chemotherapy. 2005;49:1872–1880.
http://doi.org/10.1128/AAC.49.5.1872-1880.2005 - Baraniak A & KPC–PL Study Group et al. Molecular characteristics of KPC–producing Enterobacteriaceae at the early stage of their dissemination in Poland, 2008–2009. Antimicrobial Agents and Chemotherapy. 2011;55:5493–5499.
http://doi.org/10.1128/AAC.05118-11 - Baraniak A & Gniadkowski M et al. NDM–producing Enterobacteriaceae in Poland, 2012–14: inter–regional outbreak of Klebsiella pneumoniae ST11 and sporadic cases. Journal of Antimicrobial Chemotherapy. 2016;71:85–91.
http://doi.org/10.1093/jac/dkv282 - Baraniak A, Izdebski R, Żabicka D, Bojarska K, Górska S, Literacka E, Fiett J, Hryniewicz W, Gniadkowski M, KPC–PL2 Study Group. Multiregional dissemination of KPC–producing Klebsiella pneumoniae ST258/ST512 genotypes in Poland, 2010–14. Journal of Antimicrobial Chemotherapy. 2017;72:1610–1616.
http://doi.org/10.1093/jac/dkx054 - Baraniak A, Machulska M, Żabicka D, Literacka E, Izdebski R, Urbanowicz P, Bojarska K, Herda M, Kozinska A, Hryniewicz W, Gniadkowski M, on behalf of the NDM–PL Study Group. Towards endemicity: large–scale expansion of the NDM–1–producing Klebsiella pneumoniae ST11 lineage in Poland, 2015–16. Journal of Antimicrobial Chemotherapy. 2019;74:3199–3204.
http://doi.org/10.1093/jac/dkz315 - Bauernfeind A, Schneider I, Jungwirth R, Sahly H, Ullmann U. A novel type of AmpC β–lactamase, ACC–1, produced by a Klebsiella pneumoniae strain causing nosocomial pneumonia. Antimicrobial Agents and Chemotherapy. 1999;43:1924–1931.
http://doi.org/10.1128/AAC.43.8.1924 - Biedrzycka M, Urbanowicz P, Guzek A, Brisse S, Gniadkowski M, Izdebski R. Dissemination of Klebsiella pneumoniae ST147 NDM–1 in Poland, 2015–19. Journal of Antimicrobial Chemotherapy. 2021;76:2538–2545.
http://doi.org/10.1093/jac/dkab207 - Biedrzycka M, Izdebski R, Urbanowicz P, Polańska M, Hryniewicz W, Gniadkowski M, Literacka E. MDR carbapenemase–producing Klebsiella pneumoniae of the hypervirulence–associated ST23 clone in Poland, 2009–19. Journal of Antimicrobial Chemotherapy. 2022;77:3367–3375.
http://doi.org/10.1093/jac/dkac326 - Brauncajs M, Bielec F, Macieja A, Pastuszak–Lewandowska D. Carbapenem–resistant Gram–negative fermenting and non–fermenting rods isolated from hospital patients in Poland—what are they susceptible to? Biomedicines. 2022;10:3049.
http://doi.org/10.3390/biomedicines10123049 - Bose P, Rangnekar A, Desikan P. NDM–β–lactamase–1: where do we stand? Indian Journal of Medical Research. 2022;155:243–252.
http://doi.org/10.4103/ijmr.IJMR_685_19 - Boyd S.E, Livermore D.M, Hooper D.C, Hope W.W. Metallo–β–lactamases: structure, function, epidemiology, treatment options, and the development pipeline. Antimicrobial Agents and Chemotherapy. 2020;64:e00397.
http://doi.org/10.1128/AAC.00397-20 - Bradford P.A. Extended–spectrum beta–lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clinical Microbiology Reviews. 2001; 14:933–951.
http://doi.org/10.1128/CMR.14.4.933-951.2001 - Brem J, Schofield Ch.J et al. Imitation of β–lactam binding enables broad–spectrum metallo–β–lactamase inhibitors. Nature Chemistry. 2022 Jan; 14:15–24.
http://doi.org/10.1038/s41557-021-00831-x - Bush K, Jacoby G.A. Updated functional classification of β–lactamases. Antimicrobial Agents and Chemotherapy. 2010;54:969–976.
http://doi.org/10.1128/AAC.01009-09 - Bush K. Past and present perspectives on β–lactamases. Antimicrobial Agents and Chemotherapy. 2018;62:e01076.
http://doi.org/10.1128/AAC.01076-18 - Bush K, Bradford P.A. Interplay between β–lactamases and new β–lactamase inhibitors. Nature Reviews Microbiology. 2019; 17:295–306.
http://doi.org/10.1038/s41579-019-0159-8 - Butler D.A, Rana A.P, Krapp F, Patel S.R, Huang Y, Ozer E.A, Hauser A.R, Bulman Z.P. Optimizing aminoglycoside selection for KPC–producing Klebsiella pneumoniae with the aminoglycoside–modifying enzyme (AME) gene aac(6')–Ib. Journal of Antimicrobial Chemotherapy. 2021 Mar; 76:671–679.
http://doi.org/10.1093/jac/dkaa480 - Calbo E, Garau J. The changing epidemiology of hospital outbreaks due to ESβL–producing Klebsiella pneumoniae: the CTX–M–15 type consolidation. Future Microbiology. 2015;10:1063–1075.
https://doi.org/10.2217/fmb.15.22 - Caltagirone M, Pagani L et al. Occurrence of extended spectrum β–lactamases, KPC–type, and MCR–1.2–producing Enterobacteriaceae from wells, river water, and wastewater treatment plants in Oltrepò Pavese area, northern Italy. Frontiers in Microbiology. 2017; 8:2232.
http://doi.org/10.3389/fmicb.2017.02232 - Castanheira M, Simner P.J, Bradford P.A. Extended–spectrum β–lactamases: an update on their characteristics, epidemiology and detection. JAC-Antimicrobial Resistance. 2021 Jul; 3:dlab092.
http://doi.org/10.1093/jacamr/dlab092 - Catalano A, Iacopetta D, Ceramella J, Scumaci D, Giuzio F, Saturnino C, Aquaro S, Rosano C, Sinicropi M.S. Multidrug resistance (MDR): a widespread phenomenon in pharmacological therapies. Molecules. 2022 Jan; 27:616.
http://doi.org/10.3390/molecules27030616 - Chambers H.F, Hackbarth C.J. Effect of NaCl and nafcillin on penicillin–binding protein 2a and heterogeneous expression of methicillin resistance in Staphylococcus aureus. Antimicrobial Agents and Chemotherapy. 1987;31:1982–1988.
http://doi.org/10.1128/AAC.31.12.1982 - Chong Y, Shimoda S, Shimono N. Current epidemiology, genetic evolution and clinical impact of extended–spectrum β–lactamase–producing Escherichia coli and Klebsiella pneumoniae. Infection, Genetics and Evolution. 2018;61:185–188.
http://doi.org/10.1016/j.meegid.2018.04.005 - Chung P.Y. The emerging problems of Klebsiella pneumoniae infections: carbapenem resistance and biofilm formation. FEMS Microbiology Letters. 2016;363:fnw219.
http://doi.org/10.1093/femsle/fnw219 - Codjoe F.S, Donkor E.S. Carbapenem resistance: a review. Medical Sciences. 2018;6:1–28.
http://doi.org/10.3390/medsci6010001 - Council of the European Union. Council Recommendation on stepping up EU actions to combat antimicrobial resistance in a One Health approach (2023/C 220/01). 2023.
https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=OJ:JOC_2023_220_R_0001 - Dautzenberg M.J.D, Haverkate M.R, Bonten M.J.M, Bootsma M.C.J. Epidemic potential of Escherichia coli ST131 and Klebsiella pneumoniae ST258: a systematic review and meta–analysis. BMJ Open. 2016;6:e009971.
http://doi.org/10.1136/bmjopen-2015-009971 - Ding L, Shen S, Chen J, Tian Z, Shi Q, Han R, Guo Y, Hu F. Klebsiella pneumoniae carbapenemase variants: the new threat to global public health. Clinical Microbiology Reviews. 2023;36:e00008-23.
http://doi.org/10.1128/cmr.00008-23 - Dzierżanowska D. Antybiotykoterapia praktyczna. Alfa-Medica Press; 6th edition. 2024;1–752.
- Dzierżanowska-Fangrat. Antibiotic Therapy Guide 2023. Alfa Medica Press. 2023;1–132.
- Dzierżanowska D, Kamińska W, Semczuka K, Borowiec D, Matysiak M, Szumała–Kąkol A, Gierczyński R, Patzer J.A. Carriage of genes for various extended–spectrum β–lactamases: a novel resistance strategy of Klebsiella pneumoniae in Poland. International Journal of Antimicrobial Agents. 2010;35:392–395.
http://doi.org/10.1016/j.ijantimicag.2009.12.010 - Dziewit Ł, Bartosik D. Prokaryotic genomes in the light of genomic analyses. Advances in Microbiology. 2011;50:87–96.
- European Centre for Disease Prevention and Control (ECDC). ECDC Surveillance Atlas of Infectious Diseases.
https://www.ecdc.europa.eu - Esumeh F.I, Inyang N.J, Adesina I.A, Akpe A.R, Omoigberale M.N.O, Igunbor L.A. Antibacterial susceptibility and in vitro effect of sodium chloride, magnesium ions, and serum on staphylococcal β–lactamase production in Ekpoma, Nigeria. Special Bacteriology Pathogen Journal. 2017;2:01–07.
http://doi.org/10.61915/bpj.600192 - European Centre for Disease Prevention and Control. European Antimicrobial Resistance Surveillance Network (EARS–Net).
https://ecdc.europa.eu/en/about-us/networks/disease-networks-and-laboratory-networks/ears-netabout - European Centre for Disease Prevention and Control. Antimicrobial resistance in the EU/EEA (EARS–Net) – Annual Epidemiological Report 2024. Stockholm: ECDC.
https://www.ecdc.europa.eu/en/publications-data/antimicrobial-resistance-eueea-ears-net-annual-epidemiological-report-2024 - European Centre for Disease Prevention and Control. Antimicrobial resistance in the EU/EEA (EARS–Net) – Surveillance of antimicrobial resistance in Europe, 2024 data. Stockholm: ECDC.
https://www.ecdc.europa.eu/sites/default/files/documents/antimicrobial-resistance-surveillance-Europe-2024-data.pdf - Fevre C, Passet V, Weill F.-X, Patrick A, Grimont D, Brisse S. Variants of the Klebsiella pneumoniae OKP chromosomal β–lactamase are divided into two main groups, OKP–A and OKP–B. Journal of Clinical Microbiology. 2005;43:4178–4182.
http://doi.org/10.1128/JCM.43.8.4178-4182.2005 - Fiett J, Baraniak A, Izdebski R, Sitkiewicz I, Żabicka D, Meler A, Filczak K, Hryniewicz W, Gniadkowski M. The first NDM metallo–β–lactamase–producing Enterobacteriaceae isolate in Poland: evolution of IncFII–type plasmids carrying the blaNDM–1 gene. Antimicrobial Agents and Chemotherapy. 2014;58:1203–1207.
http://doi.org/10.1128/aac.01197-13 - Galani I, Karaiskos I, Giamarellou H. Multidrug–resistant Klebsiella pneumoniae: mechanisms of resistance including updated data for novel β–lactam–β–lactamase inhibitor combinations. Expert Review of Anti-Infective Therapy. 2022;19:1457–1468.
http://doi.org/10.1080/14787210.2021.1924674 - Gniadkowski M, Palucha A, Grzesiowski P, Hryniewicz W. Outbreak of ceftazidime–resistant Klebsiella pneumoniae in a pediatric hospital in Warsaw, Poland: clonal spread of the TEM–47 extended–spectrum β–lactamase (ESβL)–producing strain and transfer of a plasmid carrying the SHV–5–like ESβL–encoding gene. Antimicrobial Agents and Chemotherapy. 1998;42:3079–3085.
http://doi.org/10.1128/AAC.42.12.3079 - Gniadkowski M, Schneider I, Jungwirth R, Hryniewicz W, Bauernfeind A. Ceftazidime–resistant Enterobacteriaceae isolates from three Polish hospitals: identification of three novel TEM– and SHV–5–type extended–spectrum β–lactamases. Antimicrobial Agents and Chemotherapy. 1998;42:514–520.
http://doi.org/10.1128/aac.42.3.514 - Guo L, An J, Ma Y, Ye L, Luo Y, Tao C, Yang J. Nosocomial outbreak of OXA–48–producing Klebsiella pneumoniae in a Chinese hospital: clonal transmission of ST147 and ST383. PLOS ONE. 2016;11:e0160754.
http://doi.org/10.1371/journal.pone.0160754 - Guzek A, Rybicki Z, Tomaszewski D, Mackiewicz K, Piechota W, Chciałowski A. Outcomes of 23 patients diagnosed with New Delhi metallo–β–lactamase (NDM)–producing Klebsiella pneumoniae infection treated with ceftazidime/avibactam and aztreonam at a single center in Poland. European Journal of Clinical Microbiology & Infectious Diseases. 2024;43:1579–1587.
http://doi.org/10.1007/s10096-024-04859-y - Hæggman S, Löfdahl S, Paauw A, Verhoef J, Brisse S. Diversity and evolution of the class A chromosomal β–lactamase gene in Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy. 2004;48:2400–2408.
http://doi.org/10.1128/AAC.48.7.2400-2408.2004 - Huang L, Wu C, Gao H, Xu C, Dai M, Huang L, Hao H, Wang X, Cheng G. Bacterial multidrug efflux pumps at the frontline of antimicrobial resistance: an overview. Antibiotics (Basel). 2022;11:520.
http://doi.org/10.3390/antibiotics11040520 - Hughes S, Gilchrist M, Heard K, Hamilton R, Sneddon J. Treating infections caused by carbapenemase–producing Enterobacterales (CPE): a pragmatic approach to antimicrobial stewardship on behalf of the UKCPA Pharmacy Infection Network (PIN). JAC-Antimicrobial Resistance. 2020;2:dlaa075.
http://doi.org/10.1093/jacamr/dlaa075 - Ishizaki Y, Shibuya Y, Hayashi C, Inoue K, Kirikae T, Tada T, Miyoshi–Akiyama T, Igarashi M. Instability of the 16S rRNA methyltransferase–encoding npmA gene: why have bacterial cells possessing npmA not spread despite their high and broad resistance to aminoglycosides? Journal of Antibiotics. 2018;1:798–807.
http://doi.org/10.1038/s41429-018-0070-y - Izdebski R & OXA–48–PL Study Group et al. Enterobacteriaceae producing OXA–48–like carbapenemases in Poland, 2013–January 2017. Journal of Antimicrobial Chemotherapy. 2018;73:620–625.
http://doi.org/10.1093/jac/dkx457 - Jacoby G.A. AmpC β–lactamases. Clinical Microbiology Reviews. 2009;22:161–182.
http://doi.org/10.1128/CMR.00036-08 - Journal of Laws of the Republic of Poland. Regulation of the Council of Ministers of March 30, 2021, on the National Health Program for 2021–2025. Warsaw, April 8, 2021, Item 642. KORLD.
- Karami–Zarandi M, Rahdar H.A, Esmaeili H, Ranjbar R. Klebsiella pneumoniae: an update on antibiotic resistance mechanisms. Future Microbiology. 2023;18:65–81.
http://doi.org/10.2217/fmb-2022-0097 - Khattab S, Askar A.M, Abdellatif H.A.A, Othman A.A.A, Rayan A.H, Azab H. Synergistic combination of ceftazidime and avibactam with aztreonam against MDR Klebsiella pneumoniae in ICU patients. Scientific Reports. 2025;15:5102.
http://doi.org/10.1038/s41598-025-88965-7 - Kiener P.A, Knott–Hunziker V, Petursson S, Waley S.G. Mechanism of substrate–induced inactivation of β–lactamase I. European Journal of Biochemistry. 1980;109:575–580.
http://doi.org/10.1111/j.1432-1033.1980.tb04830.x - Koch A.L. Autolysis control hypotheses for tolerance to wall antibiotics. Antimicrobial Agents and Chemotherapy. 2001;45:2671–2675.
http://doi.org/10.1128/AAC.45.10.2671-2675.2001 - Kowalska–Krochmal B, Woroń J, Serednicki W.T, Wordliczek J. Ceftazidime–avibactam – microbiological, pharmacological and clinical aspects in clinical practice. Forum Infectiology. 2019;10:373–381.
http://doi.org/10.15374/FZ2019056 - Krajewska J, Laudy A.E. The European Medicines Agency approved the new antibacterial drugs – response to the 2017 WHO report on the global problem of multi–drug resistance. Advances in Microbiology. 2021;60:249–264.
http://doi.org/10.21307/pm-2021.60.4.20 - Kramer A, Schwebke I, Kampf G. How long do nosocomial pathogens persist on inanimate surfaces? A systematic review. BMC Infectious Diseases. 2006;6:130.
http://doi.org/10.1186/1471-2334-6-130 - Krul D, Dalla Costa M.L. High–risk clones of carbapenem–resistant Klebsiella pneumoniae recovered from pediatric patients in Southern Brazil. Brazilian Journal of Microbiology. 2024;55:1437–1443.
http://doi.org/10.1007/s42770-024-01299-w - Kuch A, Hryniewicz W, Wanke–Rytt M, Żukowska A. Pałeczki Enterobacterales wytwarzające karbapenemazy (CPE): epidemiologia, diagnostyka, leczenie i profilaktyka zakażeń. Warszawa: Narodowy Instytut Leków; 2022.
- Laishram S, Anandan S, Devi B.Y, Elakkiya M, Priyanka B, Bhuvaneshwari T, Peter J.V, Subramani K, Balaji V. Determination of synergy between sulbactam, meropenem and colistin in carbapenem–resistant Klebsiella pneumoniae and Acinetobacter baumannii isolates and correlation with the molecular mechanism of resistance. Journal of Chemotherapy. 2016;28:297–303.
http://doi.org/10.1179/1973947815Y.0000000079 - Lee C.R, Lee J.H, Park K.S, Kim Y.B, Jeong B.Ch, Lee S.H. Global dissemination of carbapenemase–producing Klebsiella pneumoniae: epidemiology, genetic context, treatment options, and detection methods. Frontiers in Microbiology. 2016;7:1–30.
http://doi.org/10.3389/fmicb.2016.00895 - Lei T.–Y, Liao B.–B, Yang L.–R, Wang Y, Chen X.–B. Hypervirulent and carbapenem–resistant Klebsiella pneumoniae: a global public health threat. Microbiological Research. 2024;288:127839.
http://doi.org/10.1016/j.micres.2024.127839 - Li Y, Kumar S, Zhang L. Mechanisms of antibiotic resistance and developments in therapeutic strategies to combat Klebsiella pneumoniae infection. Infection and Drug Resistance. 2024;17:1107–1119.
http://doi.org/10.2147/IDR.S453025 - Liakopoulos A, Dik Mevius D, Ceccarelli D. A review of SHV extended–spectrum β–lactamases: neglected yet ubiquitous. Frontiers in Microbiology. 2016;7:1374.
http://doi.org/10.3389/fmicb.2016.01374 - Litwin A, Fedorowicz O, Duszyńska W. Characteristics of microbial factors of healthcare–associated infections including multidrug–resistant pathogens and antibiotic consumption at the University Intensive Care Unit in Poland in the years 2011–2018. International Journal of Environmental Research and Public Health. 2020;17:6943.
http://doi.org/10.3390/ijerph17196943 - Liu C, Wu Y, Fang Y, Sang Z, Huang L, Dong N, Zeng Y, Lu J, Zhang R, Chen G. Emergence of an ST1326 (CG258) multi-drug–resistant Klebsiella pneumoniae co–harboring mcr–8.2, ESβL genes, and the resistance–nodulation–division efflux pump gene cluster tmexCD1–toprJ1 in China. Frontiers in Microbiology. 2022;13:800993.
http://doi.org/10.3389/fmicb.2022.800993 - Livermore D.M. β–lactamases in laboratory and clinical resistance. Clinical Microbiology Reviews. 1995;8:557–584.
http://doi.org/10.1128/CMR.8.4.557 - Loconsole D, Accogli M, De Robertis A.L, Capozzi L, Bianco A, Morea A, Mallamaci R, Quarto M, Parisi A, Chironna M. Emerging high–risk ST101 and ST307 carbapenem–resistant Klebsiella pneumoniae clones from bloodstream infections in Southern Italy. Annals of Clinical Microbiology and Antimicrobials. 2020;19:24.
http://doi.org/10.1186/s12941-020-00366-y - Machulska M, Baraniak A, Żak I, Bojarska K, Żabicka D, Sowa–Sierant I, Hryniewicz W, Gniadkowski M. KPC–2–producing Klebsiella pneumoniae ST11 in a children's hospital in Poland. Polish Journal of Microbiology. 2017;66:401–404.
http://doi.org/10.5604/01.3001.0010.4884 - Mączyńska B, Neumann K, Junka A. Analysis of properties related to selection and survival in hospital environment of Klebsiella strains isolated from nosocomial outbreaks. Forum Infectiology. 2015;4:77–97.
http://doi.org/10.15374/fz2013013 - Mączyńska B. Evolution of pathogenicity and resistance to antibacterial agents in Klebsiella bacilli. Evereth Publishing Sp. z o.o. 2015.
- McCreary E.K, Heil E.L, Tamma P.D. New perspectives on antimicrobial agents: cefiderocol. Antimicrobial Agents and Chemotherapy. 2021;65:e02171-20.
http://doi.org/10.1128/AAC.02171-20 - Mehta S.C, Rice K, Patel T. Natural variants of the KPC–2 carbapenemase have evolved increased catalytic efficiency for ceftazidime hydrolysis at the cost of enzyme stability. PLoS Pathogens. 2015;11:e1004949.
http://doi.org/10.1371/journal.ppat.1004949 - Meini S, Tascini C, Cei M, Sozio E, Rossolini G.M. AmpC β–lactamase–producing Enterobacterales: what a clinician should know. Infection. 2019;47:363–375.
http://doi.org/10.1007/s15010-019-01291-9 - Meek R.W, Vyas H, Piddock L.J.V. Nonmedical uses of antibiotics: time to restrict their use? PLoS Biology. 2015;13:1–11.
http://doi.org/10.1371/journal.pbio.1002266 - Musawa M.A, Bleick C.R, Herbin S.R, Caniff K.E, Van Helden S.R, Rybak M.J. Aztreonam–avibactam: the dynamic duo against multidrug–resistant Gram–negative pathogens. Pharmacotherapy. 2024;44:927–938.
http://doi.org/10.1002/phar.4629 - Müderris T, Manyaslı G.D, Kaya S, Yurtsever S.G. In vitro interactions of combinations of colistin with meropenem, rifampicin and tigecycline in colistin–resistant, biofilm–forming Klebsiella pneumoniae. Diagnostic Microbiology and Infectious Disease. 2024;110:116408.
http://doi.org/10.1016/j.diagmicrobio.2024.116408 - Navon–Venezia S, Kondratyeva K, Carattoli A. Klebsiella pneumoniae: a major worldwide source and shuttle for antibiotic resistance. FEMS Microbiology Reviews. 2017;41:252–275.
http://doi.org/10.1093/femsre/fux013 - Nordmann P, Poirel L. The difficult–to–control spread of carbapenemase producers among Enterobacteriaceae worldwide. Clinical Microbiology and Infection. 2014;20:821–830.
http://doi.org/10.1111/1469-0691.12719 - Ochońska D, Brzychczy–Włoch M. Klebsiella pneumoniae – taxonomy, occurrence, identification, virulence factors and pathogenicity. Advances in Microbiology. 2024;63:157–175.
http://doi.org/10.2478/am-2024-0014 - Ochońska D, Klamińska–Cebula H, Dobrut A, Bulanda M, Brzychczy–Włoch M. Clonal dissemination of KPC–2, VIM–1, OXA–48–producing Klebsiella pneumoniae ST147 in Katowice, Poland. Polish Journal of Microbiology. 2021;70:107–116.
http://doi.org/10.33073/pjm-2021-010 - Ojdana D, Sacha P, Olszańska D, Majewski P, Wieczorek P, Jaworowska J, Sieńko A, Jurczak A, Tryniszewska E. First report of Klebsiella pneumoniae carbapenemase–3–producing Escherichia coli ST479 in Poland. BioMed Research International. 2015;2015:256028.
http://doi.org/10.1155/2015/256028 - Papanicolaou G.A, Medeiros A.A, Jacoby G.A. Novel plasmid–mediated β–lactamase (MIR–1) conferring resistance to oxyimino– and o–methoxy β–lactams in clinical isolates of Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy. 1990;34:2200–2209.
http://doi.org/10.1128/aac.34.11.2200 - Parra Sellera F, Lincopan N, Fuentes–Castillo D, Guedes Stehling E, Rueda Furlan J.P. Rapid evolution of pan–β–lactam resistance in Enterobacterales co–producing KPC and NDM: insights from global genomic analysis after the COVID–19 pandemic. The Lancet Microbe. 2024;5:e412–e413.
http://doi.org/10.1016/S2666-5247(24)00018-1 - Paterson D.L, Hujer K.M, Hujer A.M, Yeiser B, Bonomo M.D, Rice L.B, Bonomo R.A, International Klebsiella Study Group. Extended–spectrum β–lactamases in Klebsiella pneumoniae bloodstream isolates from seven countries: dominance and widespread prevalence of SHV– and CTX–M–type β–lactamases. Antimicrobial Agents and Chemotherapy. 2003;47:3554–3560.
http://doi.org/10.1128/AAC.47.11.3554-3560.2003 - Paul M, Rodríguez–Baño J. et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug–resistant Gram–negative bacilli (endorsed by European Society of Intensive Care Medicine). Clinical Microbiology and Infection. 2022;28:521–547.
http://doi.org/10.1016/j.cmi.2021.11.025 - Peirano G, Chen L, Kreiswirth B.N, Pitout J.D.D. Emerging antimicrobial–resistant high–risk Klebsiella pneumoniae clones ST307 and ST147. Antimicrobial Agents and Chemotherapy. 2020;64:e01148-20.
http://doi.org/10.1128/AAC.01148-20 - Philippon A, Redjeb S.B, Fournier G, Hassen A.B. Epidemiology of extended–spectrum β–lactamases. Infection. 1989;17:347–354.
http://doi.org/10.1007/BF01650727 - Pitout J.D.D, Nordmann P, Poirel L. Carbapenemase–producing Klebsiella pneumoniae, a key pathogen set for global nosocomial dominance. Antimicrobial Agents and Chemotherapy. 2015;59:5873–5884.
http://doi.org/10.1128/AAC.01019-15 - Pitout J.D.D, Peirano G, Kock M.M, Strydom K.–A, Matsumura Y. The global ascendency of OXA–48–type carbapenemases. Clinical Microbiology Reviews. 2019;33:e00102-19.
http://doi.org/10.1128/CMR.00102-19 - Pitton J.S. Mechanism of bacterial resistance to antibiotics. Reviews of Physiology. 1972;65:15–93.
http://doi.org/10.1007/3-540-05814-1_2 - Polish National Reference Centre for Antimicrobial Susceptibility Testing (KORLD).
https://korld.nil.gov.pl/ ,https://korld.nil.gov.pl/opornosc-na-antybiotyki-2/raporty-korld/ - Rajan R, Sasikala G. Evaluation of the in vitro efficacy of anti-microbials against Enterobacterales with multiple carbapenemase enzymes. Iranian Journal of Microbiology. 2025;17:390–396.
http://doi.org/10.18502/ijm.v17i3.18821 - State Sanitary Inspection (Poland). Report on the Activities of the State Sanitary Inspection in the Field of Public Health for 2024.
https://www.gov.pl/web/gis/raport-stan-sanitarny-kraju - Rocker A, Lacey J.A, Belousoff M.J, Wilksch J.J, Strugnell R.A, Davies M.R, Lithgow T. Global trends in proteome remodeling of the outer membrane modulate antimicrobial permeability in Klebsiella pneumoniae. mBio. 2020;11:e00603-20.
http://doi.org/10.1128/mBio.00603-20 - Rodríguez–Guerrero E, Callejas–Rodelas J.C, Navarro–Marí J.M, Gutiérrez–Fernández J. Systematic review of plasmid AmpC type resistances in Escherichia coli and Klebsiella pneumoniae and preliminary proposal of a simplified screening method for ampC. Microorganisms. 2022;10:611.
http://doi.org/10.3390/microorganisms10030611 - Sarowska J, Choroszy–Krol I, Jama–Kmiecik A, Mączyńska B, Cholewa S, Frej–Madrzak M. Occurrence and characteristics of carbapenem–resistant Klebsiella pneumoniae strains isolated from hospitalized patients in Poland – a single centre study. Pathogens. 2022;11:859.
http://doi.org/10.3390/pathogens11080859 - Sawa T, Kooguchi K, Moriyama K. Molecular diversity of extended–spectrum β–lactamases and carbapenemases, and antimicrobial resistance. Journal of Intensive Care. 2020;8:13.
http://doi.org/10.1186/s40560-020-0429-6 - Sękowska A. In vitro activity of “old” and “new” antimicrobials against the Klebsiella pneumoniae complex. Antibiotics (Basel). 2024;13:126.
http://doi.org/10.3390/antibiotics13020126 - Sękowska A. In vitro activity of plazomicin and other aminoglycosides against Klebsiella pneumoniae multidrug–resistant strains. Journal of Antibiotics. 2024;77:548–551.
http://doi.org/10.1038/s41429-024-00734-2 - Shah A.A, Alwashmi A.S.S, Abalkhail A, Alkahtani A.M. Emerging challenges in Klebsiella pneumoniae: antimicrobial resistance and novel approaches. Microbial Pathogenesis. 2025;202:107399.
http://doi.org/10.1016/j.micpath.2025.107399 - Shortridge D, Streit J.M, Mendes R, Castanheira M. In vitro activity of cefiderocol against U.S. and European Gram–negative clinical isolates collected in 2020 as part of the SENTRY antimicrobial surveillance program. Microbiology Spectrum. 2021;10:e02712-21.
http://doi.org/10.1128/spectrum.02712-21 - Sinha R, Khare S.K. Protective role of salt in catalysis and maintaining structure of halophilic proteins against denaturation. Frontiers in Microbiology. 2014;5:165.
http://doi.org/10.3389/fmicb.2014.00165 - Slain N, Lucas K, Kunz Coyne A.J. Comparison between cefepime and carbapenem therapy for deep–seated AmpC–producing Enterobacterales infections: a propensity–weighted retrospective cohort study. Antimicrobial Agents and Chemotherapy. 2025;69:e00928-25.
http://doi.org/10.1128/aac.00928-25 - Słabisz N, Leśnik P, Janc J, Fidut M, Bartoszewicz M, Dudek–Wicher R, Nawrot U. Evaluation of the in vitro susceptibility of clinical isolates of NDM–producing Klebsiella pneumoniae to new antibiotics included in a treatment regimen for infections. Frontiers in Microbiology. 2024;15:1331628.
http://doi.org/10.3389/fmicb.2024.1331628 - Stewart A, Harris P, Henderson A, Paterson D. Treatment of infections by OXA–48–producing Enterobacteriaceae. Antimicrobial Agents and Chemotherapy. 2018;62:e01195-18.
http://doi.org/10.1128/AAC.01195-18 - Subramanian G.K, Soundari P.G, Ramanathan V, Krishnan P. Endemic Indian clones of Klebsiella pneumoniae harbouring New Delhi metallo–β–lactamase–1 on a hybrid plasmid replicon type: a case of changing NDM plasmid landscapes in India? Indian Journal of Medical Microbiology. 2016;34:286–292.
http://doi.org/10.4103/0255-0857.188314 - Syed Y.Y. Cefiderocol: a review in serious Gram–negative bacterial infections. Drugs. 2021;81:1559–1571.
http://doi.org/10.1007/s40265-021-01580-4 - Szewczyk E.M. Bacteriological diagnostics. Warsaw: Państwowe Wydawnictwo Naukowe (PWN). 2019;3:1–500.
- Szymański M, Skiba M.M, Piasecka M, Olender A. Synergistic effect of ceftazidime–avibactam with aztreonam on carbapenemase–positive Klebsiella pneumoniae MBL+, NDM. Infection and Drug Resistance. 2024;17:2307–2313.
http://doi.org/10.2147/IDR. S459695 - Ślusarz K, Kurdyś P, Łanowy P, Bichalski M, Bijak B, Trejnowska E. Venovenous extracorporeal membrane oxygenation (VV ECMO) in community–acquired pneumonia caused by Klebsiella pneumoniae: what went wrong? Journal of Education, Health and Sport. 2019;9:738–746.
http://doi.org/10.5281/zenodo.3407541 - Tamma P.D, Doi Y, Bonomo R.A, Johnson J.K, Simner P.J, Antibacterial Resistance Leadership Group. A primer on AmpC β–lactamases: necessary knowledge for an increasingly multidrug–resistant world. Clinical Infectious Diseases. 2019;69:1446–1455.
http://doi.org/10.1093/cid/ciz173 - Tarski I, Śmiechowicz J, Duszyńska W. Cefiderocol in the successful treatment of complicated hospital–acquired Klebsiella pneumoniae NDM, OXA–48 intraabdominal infection. Infection and Drug Resistance. 2024;17:5163–5170.
http://doi.org/10.2147/IDR. S485450 - Tebano G, Zaghi I, Cricca M, Cristini F. Antibiotic treatment of infections caused by AmpC–producing Enterobacterales. Pharmacy (Basel). 2024;12:142.
http://doi.org/10.3390/pharmacy12050142 - Tsang K.K, KlebNETGSP AMR Genotype–Phenotype Group et al. Diversity, functional classification and genotyping of SHV β–lactamases in Klebsiella pneumoniae. Microbial Genomics. 2024;10:001294.
http://doi.org/10.1099/mgen.0.001294 - Wang Y, Zhang Q, Jin Y, Jin X, Yu J, Wang K. Epidemiology and antimicrobial susceptibility profiles of extended–spectrum β–lactamase–producing Klebsiella pneumoniae and Escherichia coli in China. Brazilian Journal of Microbiology. 2019;50:669–675.
http://doi.org/10.1007/s42770-019-00081-7 - Wantuch P.L, Rosen D.A. Klebsiella pneumoniae: adaptive immune landscapes and vaccine horizons. Trends in Immunology. 2023;44:826–844.
http://doi.org/10.1016/j.it.2023.08.005 - World Health Organization (WHO). Antimicrobial resistance surveillance in Europe 2023 – 2021 data. Copenhagen: WHO Regional Office for Europe; 2025.
https://www.who.int/ - World Health Organization (WHO). Global Antimicrobial Resistance and Use Surveillance System (GLASS). 2025.
https://www.who.int/initiatives/glass - Wyres K.L, Holt K.E. Klebsiella pneumoniae as a key trafficker of drug resistance genes from environmental to clinically important bacteria. Current Opinion in Microbiology. 2018;45:131–139.
http://doi.org/10.1016/j.mib.2018.04.004 - Wyres K.L, Lam M.M.C, Holt K.E. Population genomics of Klebsiella pneumoniae. Nature Reviews Microbiology. 2020;18:344–359.
http://doi.org/10.1016/j.mib.2018.04.004 - Wysocka M, Zamudio R, Oggioni M.R, Gołębiewska J, Bronk M, Krawczyk B. Genetic background and antibiotic resistance profiles of Klebsiella pneumoniae NDM–1 strains isolated from UTI, ABU, and the GI tract from one hospital in Poland in relation to strains nationally and worldwide. Genes. 2021;12:1285.
http://doi.org/10.3390/genes12081285 - Yahav D, Giske C.G, Grāmatniece A, Abodakpi H, Tam V.H, Leibovici L. New β–lactam–β–lactamase inhibitor combinations. Clinical Microbiology Reviews. 2020;34:e00115-20.
http://doi.org/10.1128/CMR.00115-20 - Yang X, Sun Q, Li J, Jiang Y, Li Y, Lin J, Chen K, Chan E.W.C, Zhang R, Chen S. Molecular epidemiology of carbapenem–resistant hypervirulent Klebsiella pneumoniae in China. Emerging Microbes & Infections. 2022;11:841–849.
http://doi.org/10.1080/22221751.2022.2049458 - van Duin D, Cober E, Richter S.S, Perez F, Kalayjian R.C, Salata R.A, Evans S, Fowler V.G Jr, Bonomo R.A, Kaye K.S. Residence in skilled nursing facilities is associated with tigecycline non–susceptibility in carbapenem–resistant Klebsiella pneumoniae. Infection Control & Hospital Epidemiology. 2015;36:942–948.
http://doi.org/10.1017/ice.2015.118 - van Duin D, Paterson D.L. Multidrug–resistant bacteria in the community: an update. Infectious Disease Clinics of North America. 2020;34:709–722.
http://doi.org/10.1016/j.idc.2020.08.002 - Yoon E–J, Jeong S.H. Class D β–lactamases. Journal of Antimicrobial Chemotherapy. 2021;76:836–864.
http://doi.org/10.1093/jac/dkaa513 - Yuan P.–B, Dai L.–T, Zhang Q.–K, Zhong Y.–X, Liu W.–T, Yang L, Chen D.–Q. Global emergence of double and multi–carbapenemase producing organisms: epidemiology, clinical significance, and evolutionary benefits on antimicrobial resistance and virulence. Microbiology Spectrum. 2024;12:e00008-24.
http://doi.org/10.1128/spectrum.00008-24
Language: English, Polish
Page range: 56 - 80
Submitted on: Apr 30, 2025
Accepted on: May 19, 2026
Published on: Jul 28, 2026
Published by: Polish Society of Microbiologists
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Related subjects:
© 2026 Dorota Ochońska, Monika Brzychczy–Włoch, published by Polish Society of Microbiologists
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.